UCSD’s Anthony Wynshaw-Boris Named Executive Editor of Human Molecular Genetics

 

September 21, 2005  |  

Anthony Wynshaw-Boris, M.D., Ph.D., director of the University of California, San Diego (UCSD) School of Medicine’s Center for Human Genetics and Genomics, has been named executive editor of the journal Human Molecular Genetics, which concentrates on research covering a wide range of topics in all aspects of human molecular genetics.

Wynshaw-Boris succeeds Huntington Willard, Ph.D., vice chancellor and director of the Institute for Genome Sciences and Policy at Duke University, who has served as the journal’s executive editor for 14 years.

In addition to his new role as the journal’s executive editor, Wynshaw-Boris will continue his duties as a UCSD professor of pediatrics and medicine, and chief of the Division of Genetics within the UCSD Department of Pediatrics. He has been a UCSD faculty member and medical researcher since 1999. Prior to that, he was head of Mouse Models Unit within the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health.

Wynshaw-Boris is a Del Mar, California resident.

##

News Media Contact:

Sue Pondrom, 619-543-6163, spondrom@ucsd.edu

UCSD Health Sciences Communications HealthBeat: /news/

 




Media Contact

Share This Article


Related News

7/20/2017
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) today unanimously approved a $5.8 million award to University of California San Diego School o ...
7/10/2017
UC San Diego Health has been named one of the nation’s “Most Wired” health systems by Hospitals & Health Networks magazine, a publication of the American Hospital Association. The award recognizes hos ...
7/10/2017
Researchers at University of California San Diego School of Medicine have discovered differences in how the brain responds to food rewards in individuals with a history of bulimia nervosa (BN), an eat ...
7/5/2017
After 12 weeks of taking an anti-asthma drug, a subset of patients with type 2 diabetes showed a clinically significant reduction in blood glucose during a randomized, double blind, placebo-controlled ...



Follow Us